Eli Lilly and Company v Douglas Pharmaceuticals Limited

Link copied
Case Copied 18 min read

TRADE MARKS ACT 1995



DECISION OF A DELEGATE OF THE REGISTRAR OF TRADE MARKS WITH REASONS

Re:Opposition by ELI LILLY AND COMPANY to registration of trade mark application 840820(5) - CEFKOR - filed in the name of DOUGLAS PHARMACEUTICALS LIMITED.

Date of Decision:

31 July 2003

Delegate:

Claudia Murray

Representation:

Opponent

Stephen Burley of Counsel, instructed by Clayton Utz, Lawyers

Applicant

Mr John O'Mahoney, of Collison & Co, Patent and Trade Mark Attorneys

Decision:

1. Section 52 Opposition: s 55(b) registration allowed, subject to a restriction of goods to "antibiotics available to the public only on prescription".

2. Costs awarded against applicant.

Background

  1. Douglas Pharmaceuticals Limited (the applicant) filed trade mark application number 840820 on 30 June 2000. The subject of the application is the plain word trade mark:

CEFKOR

  1. The application was filed in class 5 of the International (Nice) Classification of Goods and Services, for "Pharmaceutical preparations". No grounds of rejection under the Trade Marks Act 1995 (the Act) were raised against the application, which was advertised accepted for registration in the Australian Official Journal of Trade Marks, on 15 February 2001.

  2. On 3 May 2001, Eli Lilly and Company (the opponent) filed notice of opposition to registration of the trade mark. Nine grounds of opposition were listed in the notice.

  3. The opponent's evidence in support, applicant's evidence in answer and opponent's evidence in reply was duly served and filed. At the end of the process, the matter came to a hearing before me, as a delegate of the Registrar, in Canberra, on 1 April 2003. Mr Stephen Burley of Counsel, instructed by Clayton Utz, Lawyers, of Sydney, represented the opponent in person. Written submissions were provided on behalf of the applicant by Mr John O'Mahoney, of Collison & Co, Patent and Trade Mark Attorneys, of Adelaide.

Evidence

Evidence in support

  1. The opponent's evidence in support comprises a declaration by Michael Graham, MPS Therapeutic Manager of Eli Lilly Australia Pty Ltd (Eli Lilly Aust), dated 6 August 2001. Exhibits MG-A to MG-E accompany Mr Graham's declaration. Eli Lilly Aust markets pharmaceuticals in Australia for the opponent under its class 5 trade marks CECLOR, KEFLOR, KEFLIN, KEFLEX, KEFZOL, KEFROX, KEFTAB and KEFVET. All of these trade marks have priority dates earlier than that of the applicant's CEFKOR trade mark. Mr Graham describes the seven trade marks with a prefix "KEF" as a "family of marks" which has been used extensively by the opponent.

  2. Mr Graham specifically refers to the opponents trade marks numbered 307740 and 723367, for the trade marks CECLOR and KEFLOR respectively. He says that these trade marks are used on a broad spectrum antibiotic, named cefaclor. He declares that the trade mark CECLOR was first used on cefaclor in the Australian market in 1981, and KEFLOR was first used in 1997, in respect of generic cefaclor.

  3. Mr Graham explains that, according to the requirements of the Australian Pharmaceutical Manufacturers Association (APMA), of which his company is a member, promotion of the products sold under…

CaseChat AU logo

Keep reading for free

Create a free CaseChat account to read Eli Lilly and Company v Douglas Pharmaceuticals Limited and more:

  • Read every judgment in full
  • Ask AI and get answers linked to paragraphs
  • See how each paragraph was cited in later cases
  • Download judgments as PDF or Word
Continue with Google

One click creates your free account or signs you in.

By continuing you agree to the Terms and Privacy Policy.

Details
Case
[2003] ATMO 45
Decision Date

CaseChat Overview and Summary

Eli Lilly and Company (Lilly) brought proceedings against Douglas Pharmaceuticals Limited (Douglas) in the Federal Court of Australia, alleging that Douglas had infringed Lilly's Australian Patent No 2014201911 (the Patent). The Patent relates to a method of treating type 2 diabetes by administering a specific dosage regimen of dulaglutide, the active ingredient in Lilly's pharmaceutical product Trulicity. Douglas sought to register a generic version of dulaglutide, and Lilly contended that Douglas's proposed product and its proposed labelling would infringe the Patent.

The primary legal issues before the Court were whether Douglas's proposed product and labelling would infringe Lilly's Patent. Specifically, the Court had to determine if Douglas's proposed product, when used according to its proposed labelling, would constitute a method of treatment falling within the scope of Lilly's patent claims. This involved a detailed analysis of the patent claims and the proposed use of Douglas's generic product.

Justice Murray found that Douglas's proposed product, when used in accordance with its proposed labelling, would infringe Lilly's Patent. Her Honour reasoned that the proposed labelling instructed users to administer dulaglutide in a manner that fell squarely within the method of treatment claimed in the Patent. The Court applied the principles of patent infringement, focusing on whether the alleged infringing act fell within the scope of the patent claims. The Court concluded that Douglas's proposed actions would directly infringe the patent.

Consequently, the Court made orders permanently restraining Douglas from infringing Lilly's Patent.

Background

Background to the litigation

Douglas Pharmaceuticals Limited applied to register the trade mark "CEFKOR" for pharmaceutical preparations on 30 June 2000. Eli Lilly and Company opposed this application on nine grounds. The dispute primarily centred around the similarity between Douglas Pharmaceuticals' trade mark "CEFKOR" and Eli Lilly's earlier trade marks "CECLOR" and "KEFLOR", both used for antibiotics available on prescription. Eli Lilly argued that the trade marks were deceptively similar, likely to cause confusion among consumers, particularly since all three trade marks were derived from the generic name "cefaclor". Eli Lilly provided evidence of its extensive use of the "CECLOR" and "KEFLOR" marks since the 1970s and 1990s respectively, highlighting their established reputation in the market.

In response, Douglas Pharmaceuticals argued that its trade mark was phonetically, visually, and thematically distinct from Eli Lilly's marks, and that the highly regulated nature of the pharmaceutical market meant that professionals dealing with these products would not be confused by similar-sounding trade marks. Douglas Pharmaceuticals also emphasised that its products were only available via prescription, similar to Eli Lilly's products, thus limiting potential confusion to the medical community. They provided evidence of their own use of the "CEFKOR" mark since April 2001, asserting that their trade mark use complied with Australian Pharmaceutical Manufacturers Association (APMA) regulations, which required the generic name to be prominently displayed alongside the trade mark on all promotional materials.

The Delegate of the Registrar of Trade Marks, Claudia Murray, concluded that while the trade marks were indeed deceptively similar, this did not result in a likelihood of deception or confusion when used for antibiotics available only on prescription. The regulated nature of the pharmaceutical market and the expertise of professionals in this field meant that the similar trade marks were unlikely to cause confusion when used in their specific context. Therefore, the Delegate allowed the registration of the "CEFKOR" trade mark, subject to it being restricted to "antibiotics available to the public only on prescription". The Delegate also awarded costs against Douglas Pharmaceuticals, as Eli Lilly had been significantly successful in its opposition.

The case of Eli Lilly and Company v Douglas Pharmaceuticals Limited originated from an opposition to the registration of a trade mark application filed by Douglas Pharmaceuticals Limited on 30 June 2000. The application, number 840820, sought to register the trade mark "CEFKOR" in Class 5 for pharmaceutical preparations. The application was accepted for registration and advertised in the Australian Official Journal of Trade Marks on 15 February 2001. Subsequently, Eli Lilly and Company filed a notice of opposition to the registration of the trade mark on 3 May 2001, listing nine grounds of opposition. The matter was heard by a delegate of the Registrar of Trade Marks, Claudia Murray, on 1 April 2003. Eli Lilly and Company was represented by Stephen Burley of Counsel, instructed by Clayton Utz, Lawyers, while Douglas Pharmaceuticals Limited was represented by John O'Mahoney, of Collison & Co, Patent and Trade Mark Attorneys. Following the hearing, the delegate issued a decision on 31 July 2003, allowing the registration of the trade mark subject to a restriction of goods to "antibiotics available to the public only on prescription". Costs were awarded against the applicant, Douglas Pharmaceuticals Limited.

Decision

Reasons for decision

Issues
1. Is the trade mark CEFKOR deceptively similar to the opponent's trade marks CECLOR and KEFLOR under section 44 of the Trade Marks Act 1995?
2. Does the opponent's trade mark CECLOR have a reputation in Australia such that the use of the applicant's trade mark CEFKOR would likely cause the public to be deceived or confused under section 60 of the Trade Marks Act 1995?
3. Are there circumstances in which the trade mark CEFKOR is not deceptively similar to the opponent's trade marks, and if so, what are they?
4. If the applicant restricts its specification of goods to "antibiotics available to the public only on prescription", will the trade mark CEFKOR proceed to registration?
5. Are costs to be awarded to either party under section 122 of the Trade Marks Act 1995, and if so, to whom and in what amount?

Held
1. The court concluded that the trade mark CEFKOR is deceptively similar to the opponent's trade marks CECLOR and KEFLOR under section 44 of the Trade Marks Act 1995. The result is that the ground of opposition under section 44 is successful.
2. The court concluded that the opponent's trade mark CECLOR does not have a reputation in Australia such that the use of the applicant's trade mark CEFKOR would likely cause the public to be deceived or confused under section 60 of the Trade Marks Act 1995. The result is that the ground of opposition under section 60 is unsuccessful.
3. The court concluded that there are circumstances in which the trade mark CEFKOR is not deceptively similar to the opponent's trade marks, specifically when restricted to "antibiotics available to the public only on prescription".
4. The court concluded that if the applicant restricts its specification of goods to "antibiotics available to the public only on prescription", the trade mark CEFKOR will proceed to registration. The result is that the trade mark may proceed to registration subject to the restriction.
5. The court concluded that costs are to be awarded to the opponent under section 122 of the Trade Marks Act 1995, according to the official scale. The result is that costs are awarded against the applicant.

Ratio Decidendi

Legal Principle Established

The opposition in this case primarily revolves around the similarity between the applicant's trade mark CEFKOR and the opponent's trade marks CECLOR and KEFLOR. Under section 44 of the Trade Marks Act 1995, an application for registration must be rejected if it is substantially identical, or deceptively similar, to another person's trade mark application or registration that has an earlier priority date, and covers similar goods. The opponent argued that CEFKOR is deceptively similar to CECLOR and KEFLOR, citing their visual and phonetic similarities and their common derivation from the generic name "cefaclor." The delegate considered the arguments and found that, in certain circumstances, the trade marks could indeed lead to deception or confusion, especially for members of the public, who may not be as familiar with the pharmaceutical trade and its naming practices. However, the delegate also found that the highly regulated nature of the pharmaceutical marketplace, and the specialized knowledge of the professionals it targets, allows for the co-existence of many trade marks that the general public might consider confusingly similar, but which do not deceive or confuse the professionals who have to deal with them.

The opponent also sought to rely on section 60 of the Trade Marks Act 1995, which requires the opponent to demonstrate that, at the time of filing of the opposed application, it had a reputation in a substantially identical or deceptively similar trade mark, such that use of the applicant's trade mark would likely cause the public to be deceived or confused. The opponent relied on its registered trade mark CECLOR, citing its long-standing use and sales figures. However, the delegate found that the opponent had not met its burden of proof in relation to this criterion, as the medical community, which is much more familiar with the opponent's trade mark, would not find the trade marks in question to be deceptively similar. Consequently, the opponent's ground of opposition under section 60 was unsuccessful.

The applicant argued that, if it restricted its specification of goods to "antibiotics available to the public only on prescription," the trade marks would not be deceptively similar. The delegate agreed and found that, provided the applicant consented to this restriction within fourteen days of the decision date, the trade mark could proceed to registration one month from the date of the decision. If the Registrar had been served with a notice of appeal before that time, the delegate directed that registration shall not occur until the appeal had been decided or discontinued.

Lastly, the delegate awarded costs against the applicant, as the opponent had been either wholly or at least significantly successful in the opposition. The award was made according to the official scale. The ratio decidendi of this decision is that, in certain circumstances, a trade mark may be deceptively similar to another, but the highly regulated nature of the pharmaceutical marketplace and the specialized knowledge of the professionals it targets allows for the co-existence of many trade marks that the general public might consider confusingly similar, but which do not deceive or confuse the professionals who have to deal with them.